Leerink Partners Remains a Hold on 908 Devices (MASS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: 908 Devices (MASS), LENZ Therapeutics (LENZ) and Johnson & Johnson (JNJ)
Stifel Maintains 908 Devices(MASS.US) With Buy Rating, Maintains Target Price $6
William Blair Maintains 908 Devices(MASS.US) With Buy Rating
William Blair Sticks to Its Buy Rating for 908 Devices (MASS)
William Blair Maintains 908 Devices(MASS.US) With Buy Rating
TD Cowen Maintains 908 Devices(MASS.US) With Buy Rating
William Blair Maintains 908 Devices(MASS.US) With Buy Rating
908 Devices: Strategic Divestiture and Strong Financial Performance Drive Buy Rating
Repligen's Strategic Acquisition of 908 Devices' Assets: A Buy Rating for Long-term Shareholder Value
Leerink Partners Maintains 908 Devices(MASS.US) With Hold Rating, Announces Target Price $5
908 Devices (MASS) Gets a Hold From Leerink Partners
Stifel Maintains 908 Devices(MASS.US) With Buy Rating, Maintains Target Price $6
TD Cowen Maintains 908 Devices(MASS.US) With Buy Rating
William Blair Maintains 908 Devices(MASS.US) With Buy Rating
William Blair Sticks to Its Buy Rating for 908 Devices (MASS)
908 Devices (MASS) Receives a Hold From Leerink Partners
Stephens Maintains 908 Devices(MASS.US) With Buy Rating, Cuts Target Price to $6
908 Devices Analyst Ratings
Stephens & Co. Reiterates Overweight on 908 Devices, Maintains $6 Price Target